FDA Approves New Diabetes Drug Formulation for AstraZenaca

October 25, 2017

The FDA approved a new formulation of AstraZenaca’s type-2 diabetes treatment Bydureon, the company said.

The approval includes administration by a modified once-weekly, single-dose autoinjector device, the company said.

Bydureon is indicated for adults with type-2 diabetes whose blood sugar remains uncontrolled on one or more oral medicines in addition to diet and exercise.

View today's stories